(Q35004120)

5 August 2017

MicroRNA-221 silencing predisposed human bladder cancer cells to undergo apoptosis induced by TRAIL. (English)

1 reference

5 August 2017

1 reference

1 reference

Qiang Lu

1

1 reference

5 August 2017

Chao Lu

2

1 reference

5 August 2017

Guo-Ping Zhou

3

1 reference

5 August 2017

Wei Zhang

4

1 reference

5 August 2017

Hang Xiao

5

1 reference

5 August 2017

Xin-Ru Wang

6

1 reference

5 August 2017

19 September 2009

1 reference

5 August 2017

1 reference

5 August 2017

28

1 reference

5 August 2017

635-641

1 reference

5 August 2017

6

1 reference

Potential of urinary biomarkers in early bladder cancer diagnosis

5 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.06.005

Proteome-based diagnostics and prognosis of bladder transitional cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.06.005

Bladder cancer biomarkers: current developments and future implementation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.06.005

Clinical applications for targeted therapy in bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.06.005

Integrating perioperative chemotherapy into the treatment of muscle-invasive bladder cancer: strategy versus reality.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.06.005

Carcinoma in situ of the urinary bladder: review of clinicopathologic characteristics with an emphasis on aspects related to molecular diagnostic techniques and prognosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.06.005

Screening for bladder cancer: theoretical and practical issues in considering the treated and untreated natural history of the various forms of the disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.06.005

A meta-analysis of randomised trials suggests a survival benefit for combined radiotherapy and radical cystectomy compared with radical radiotherapy for invasive bladder cancer: are these data relevant to modern practice?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.06.005

Survival rates after radical cystectomy according to tumor stage of bladder carcinoma at first presentation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.06.005

The type 1 insulin-like growth factor receptor is over-expressed in bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.06.005

The treated natural history of high risk superficial bladder cancer: 15-year outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.06.005

Natural history of superficial bladder tumors: 10- to 20-year follow-up of treated patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.06.005

In vitro efficacy of Fas ligand gene therapy for the treatment of bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.06.005

Norsolorinic acid inhibits proliferation of T24 human bladder cancer cells by arresting the cell cycle at the G0/G1 phase and inducing a Fas/membrane-bound Fas ligand-mediated apoptotic pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.06.005

Origins and Mechanisms of miRNAs and siRNAs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.06.005

MicroRNAs: target recognition and regulatory functions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.06.005

MicroRNA silencing in primates: towards development of novel therapeutics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.06.005

MicroRNAs as biomarkers and therapeutic drugs in human cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.06.005

MicroRNAs and cancer: past, present, and potential future

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.06.005

The putative tumor suppressor microRNA-101 modulates the cancer epigenome by repressing the polycomb group protein EZH2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.06.005

miR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27Kip1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.06.005

The promyelocytic leukemia zinc finger-microRNA-221/-222 pathway controls melanoma progression through multiple oncogenic mechanisms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.06.005

Role of phosphatidylinositol-3 kinase/Akt pathway in bladder cancer cell apoptosis induced by tumor necrosis factor-related apoptosis-inducing ligand

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.06.005

Micro-RNA profiling in kidney and bladder cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.06.005

Post-translational regulation of the tumor suppressor p27(KIP1).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.06.005

The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.06.005

Effects of physiologic pacing versus ventricular pacing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.06.005

Apoptosis and chemotherapy for bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.06.005

Bladder cancer detection with urinary survivin, an inhibitor of apoptosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.06.005

Response of bladder carcinoma cells to TRAIL and antisense oligonucleotide, Bcl-2 or clusterin treatments.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.06.005

Neutrophils and TRAIL: insights into BCG immunotherapy for bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.06.005

MicroRNA signatures of TRAIL resistance in human non-small cell lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.06.005

10.1016/J.UROLONC.2009.06.005

7 January 2021

Identifiers

DOI

1 reference

5 August 2017

1 reference